ProfileGDS4814 / ILMN_1788099
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 97% 97% 97% 97% 97% 97% 97% 97% 96% 97% 97% 96% 96% 97% 97% 97% 97% 97% 98% 97% 97% 98% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)1301.5397
GSM780708Untreated after 4 days (C2_1)1342.897
GSM780709Untreated after 4 days (C3_1)1382.8997
GSM780719Untreated after 4 days (C1_2)1323.197
GSM780720Untreated after 4 days (C2_2)1551.7897
GSM780721Untreated after 4 days (C3_2)1526.6497
GSM780710Trastuzumab treated after 4 days (T1_1)1372.5997
GSM780711Trastuzumab treated after 4 days (T2_1)1384.4297
GSM780712Trastuzumab treated after 4 days (T3_1)1145.4596
GSM780722Trastuzumab treated after 4 days (T1_2)1442.1597
GSM780723Trastuzumab treated after 4 days (T2_2)1442.1597
GSM780724Trastuzumab treated after 4 days (T3_2)1163.5596
GSM780713Pertuzumab treated after 4 days (P1_1)1257.6996
GSM780714Pertuzumab treated after 4 days (P2_1)1289.2797
GSM780715Pertuzumab treated after 4 days (P3_1)1454.7597
GSM780725Pertuzumab treated after 4 days (P1_2)1477.8497
GSM780726Pertuzumab treated after 4 days (P2_2)1442.1597
GSM780727Pertuzumab treated after 4 days (P3_2)1431.9897
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)1842.0598
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)1663.1697
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)1536.7197
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)2021.5698
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)1433.0297